New Two-Pronged attack on advanced prostate cancer begins human testing
NCT ID NCT07115446
Summary
This early-stage study is testing the safety and side effects of a new two-drug combination for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The trial combines an antibody-drug (HS-20093) that targets cancer cells with a second drug (HRS-5041) designed to degrade the hormone receptors that fuel the cancer. The main goal is to find the highest dose patients can tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.